Polycystic ovary syndrome affects 8–13% of reproductive-age women. Insulin resistance is central to its pathophysiology. GLP-1 receptor agonists — by improving insulin sensitivity and reducing weight — address the metabolic core of PCOS, and emerging evidence shows clinical benefit on cycle regularity, ovulation, and metabolic markers.

Why GLP-1 makes sense in PCOS

PCOS is characterized by:

GLP-1 receptor agonists improve insulin sensitivity, reduce body weight, and (downstream) reduce ovarian androgen production. The mechanism aligns directly with PCOS pathophysiology.

The evidence — small but consistent

PCOS-specific phase 3 trial data are limited but accumulating. Several smaller randomized trials and observational cohorts show:

Larger trials (PCOS-specific phase 3 programs) are not yet running, but the off-label use is common and supported by mechanism.

The fertility consideration

This is the most consequential clinical issue. GLP-1 therapy frequently restores ovulation in patients with weight-related anovulation — including patients who had been previously infertile. The combination of "I started GLP-1 therapy and unexpectedly conceived" is well documented in PCOS practice.

Practical implications:

Hirsutism and androgen effects

Improvements in hirsutism on GLP-1 therapy are typically modest and slow. The dominant driver is reduction in fasting insulin → reduced ovarian androgen production. Patients with significant hirsutism does not expect rapid cosmetic improvement; the benefit is gradual and is one piece of a broader treatment plan that may include anti-androgens (spironolactone) and laser/electrolysis.

How PCOS-specific telehealth fits

Most compounded GLP-1 telehealth programs we review market primarily for weight management, not for PCOS-specific care. Patients with PCOS considering compounded GLP-1 should:

What about metformin and other PCOS therapies?

Metformin has been the standard insulin-sensitizing agent in PCOS for decades. Effect sizes on weight, cycle regularity, and ovulation are modest. GLP-1 receptor agonists appear meaningfully more effective on these endpoints, especially when weight is a contributing factor. Combination metformin + GLP-1 is common; consider this with the prescriber.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.